Abstract
Forty-seven patients with stage III nonsmall cell lung cancer (NSCLC) were treated with the sequential administration of combination chemotherapy consisting of cisplatin, epirubicin and etoposide and of irradiation plus lonidamine. The response rate was 49% after chemotherapy with an improvement of 14% after radiation therapy and lonidamine. The median survival was around 15 months for responders and 9 months for nonresponders. Toxicity was moderate and acceptable. It is concluded that this schedule is active in the treatment of NSCLC.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Adenocarcinoma / radiotherapy*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / radiotherapy*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / radiotherapy*
-
Combined Modality Therapy
-
Female
-
Humans
-
Indazoles / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / radiotherapy*
-
Male
-
Middle Aged